Seres Therapeutics, Inc.

NASDAQ:MCRB

Biotechnology

Healthcare
$5.28 +1.70%

+$0.11 today

Market cap
$51.13M
Beta
0.11
P/E (TTM)
-1.3
EPS (TTM)
-$4.89
52W Low $5.31High $29.98

Volume 0.04M

Average 0.06M

MCRB Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Seres Therapeutics, Inc.NASDAQ: MCRB

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses declines year over year

Q1 FY2026 other income / expenses of $994K fell 98.3% year over year, behind the -24.4% change in trailing-twelve-month other income / expenses. Sequentially, it fell 75.4% from the prior quarter.

Context

  • Other income / expenses amounted to 12632.1% of revenue in FY2025.
  • Other income / expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -98.3% toward the trailing-twelve-month pace of -24.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$994K-75.4% QoQ
Last fiscal yearDec 2025
$99.67M+2336.7% YoY
LTMMar 2026
$40.74M-24.4% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-98.3%——
1 year+2336.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
99.67M USD
Year-over-year change
+2336.7%

Other Income / Expenses vs competitors

How MCRB compares with its peers on the latest reported figures

  • MCRB's LTM Mar 2026 other income / expenses of $40.74M is the highest of the 9 companies compared; the peer median is $1.36M.
  • Its year-over-year change of -24.4% is the 4th highest of 9, against a peer median of -55.8%.
  • Other income / expenses amounts to 3552.1% of revenue for MCRB, versus a peer median of 28.4%.
MCRB Competitors Peer median
Other Income / Expenses for MCRB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MCRBSeres Therapeutics, Inc.LTM Mar 2026$40.74M -24.4%—3552.1%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$23.26M +14.4%+3.1%—
SEERSeer, Inc.LTM Mar 2026$4.27M -57.4%-0.2%28.4%
SPROSpero Therapeutics, Inc.LTM Mar 2026$1.99M -54.2%—3.6%
HURATuHURA Biosciences, Inc.LTM Mar 2026$1.38M +179.7%+128.1%—
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$1.34M -87.1%+1.6%—
ACTUActuate Therapeutics IncLTM Mar 2026$299.11K +119.3%+78.0%—
INOInovio Pharmaceuticals, Inc.LTM Mar 2026-$1.21M -112.8%——
IRDOpus Genetics, Inc.LTM Mar 2026-$63.9M -1226.0%—533.2%
Peer median (excluding MCRB) $1.36M-55.8%+3.1%28.4%

Competitors are the stored peer set for MCRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue144.93M000789K
Cost of Revenue0019.34M3.53M4.13M
Gross Profit144.93M0(19.34M)(3.53M)(3.34M)
Gross Margin100.0%———-423.8%
Research & Development141.89M109.65M117.6M64.6M49.06M
Selling, General & Admin69.26M70.26M77.5M53.18M39.16M
Operating Expenses209.42M179.91M175.76M117.78M90.63M
Depreciation & Amortization5.95M6.63M6.24M5.47M4.13M
EBITDA(56.72M)(170.93M)(181.42M)(120.3M)9.83M
EBITDA Margin-39.1%———1245.8%
Operating Income(64.49M)(179.91M)(195.1M)(121.32M)(93.97M)
Operating Margin-44.5%———-11910.1%
Interest Income2.87M3.06M7.3M3.97M2.23M
Interest Expense2.91M6.02M13.18M00
Other Income / Expenses(1.09M)(3.67M)4.97M(4.46M)99.67M
Income Before Tax(65.58M)(183.58M)(190.13M)(125.77M)5.7M
Pre-Tax Margin-45.2%———721.9%
Income Tax Expense00000
Net Income(65.58M)(250.16M)(113.72M)(146.57M)5.7M
Net Margin-45.2%———721.9%
EPS (Basic)(14.30)(46.29)(17.77)(18.86)0.64
EPS (Diluted)(14.30)(46.29)(17.77)(18.86)0.64
Weighted Avg Shares4.59M5.4M6.4M7.77M8.86M
Weighted Avg Shares (Diluted)4.59M5.4M6.4M7.77M8.87M

Seres Therapeutics, Inc.

NASDAQ:MCRB

Intrinsic Alpha fair value

Locked

Current Price

$5.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.